DOCSLIB.ORG

Disclaimer COVID-19 Evidence Support Team EVIDENCE SEARCH

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disclaimer COVID-19 Evidence Support Team EVIDENCE SEARCH COVID-19 Evidence Support Team EVIDENCE SEARCH REPORT Review Question: How effective are COVID-19 vaccines? Context: Benefits following dose/second dose; how well it prevents infections; evidence of limiting viral replication or spread; preventing hospitalization; preventing ventilation; preventing “long COVID” (long term symptoms), duration of immunity (natural and vaccinated). FDA cold chain changes. Effectiveness against P1 variant. Booster doses for variants. Does not include vaccine willingness/acceptance (to be run as a separate search) Review Code: INF031801v2 ESR Complete Date: April 14, 2021 Cite As: Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2021 Apr 14, Document no.: INF031801v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 69 p. (CEST rapid review report). Librarian Notes & Comments Greetings, We received 181 new references re: vaccine safety/efficacy since the last search was conducted on March 17 2021 from MEDLINE. We have also included news & grey literature when applicable. Sincerely, Lukas & Brianna Disclaimer This information is provided as a service by the Saskatchewan Health Authority and University of Saskatchewan Libraries. Professional librarians conduct searches of the literature. Results are subject to the limitations of the databases and the specificity, broadness and appropriateness of the search parameters presented by the requester. The Libraries do not represent in any matter that retrieved citations are complete, accurate or otherwise to be relied upon. The search re sults are only valid as of the date and time at which the search is conducted. The Libraries do not accept responsibility for any loss or damage aris ing from the use of, or reliance on, search results. Search Results: Guidelines, Summaries & Other Grey Literature Government Health Canada Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply. April 9, 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee- on-immunization-naci/extended-dose-intervals-covid-19-vaccines-early-rollout-population- protection.html Archived 5: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada [2021-03-03]. March 3, 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee- on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout- population-protection.html BCCDC Monitoring vaccine uptake, safety and effectiveness. April 13, 2021. http://www.bccdc.ca/health-info/diseases-conditions/covid-19/covid-19-vaccine/monitoring- vaccine-uptake-safety-and-effectiveness CDC / FDA Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html National Immunization Technical Advisory Groups (Germany) 2nd STIKO update of the COVID-19 Vaccination recommendation and the associated scientific Reason. 2021. https://www.nitag-resource.org/media-center/2nd-stiko-update-covid-19- vaccination-recommendation-and-associated-scientific-reason STIKO Decision of the STIKO for the recommendation of the COVID-19 vaccination and the corresponding scientific rationale (2nd update). February 4, 2021. https://www.rki.de/EN/Content/infections/Vaccination/recommandations/COVID-19-2nd- update.pdf?__blob=publicationFile#:~:text=In%20regard%20to%20the%20licensing,of%209%20 to%2012%20weeks. Agency for Clinical Innovation and New South Wales Government What evidence is emerging regarding the effectiveness of the AstraZeneca vaccine, particularly regarding hospitalizations in the United Kingdom (UK)?. March 14, 2021. https://aci.health.nsw.gov.au/__data/assets/pdf_file/0003/637464/Evidence-Check- AstraZeneca-and-rollout.pdf WHO Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine. April 7, 2021. Evidence Search Report: INF031801v2 ESR 2 https://www.who.int/news/item/07-04-2021-interim-statement-of-the-covid-19- subcommittee-of-the-who-global-advisory-committee-on-vaccine-safety Evaluation of COVID-19 vaccine effectiveness: interim guidance. March 17, 2021. https://apps.who.int/iris/handle/10665/340301 European Centre for Disease Prevention and Control Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination. March 29, 2021. https://www.ecdc.europa.eu/en/publications- data/sars-cov-2-transmission-newly-infected-individuals-previous-infection Wisconsin Department of Health Services COVID-19: Vaccine Safety and Efficacy. April 13, 2021. https://www.dhs.wisconsin.gov/covid- 19/vaccine-safety.htm Clinical Trials Clinical Trials.gov A Study to Evaluate Safety and Effectiveness of mRNA-1237 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age. April 13, 2021. https://clinicaltrials.gov/ct2/show/NCT04796896 A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2. S in Healthy Adults and Adolescents. April 12, 2021. https://clinicaltrials.gov/ct2/show/NCT04535453 Trial Scope A COVID-19 vaccine study for children. n.d. https://connect.trialscope.com/studies/0e8fc8e6- 5782-46fd-8b03-0994a5ad8b41 White Papers Healthy Debate Comparing vaccines: efficacy, safety and side effects. March 11, 2021. https://healthydebate.ca/2021/03/topic/comparing-vaccines/ Institute for Health Metrics and Evaluation, University of Washington COVID-19 vaccine efficacy summary. March 4, 2021. http://www.healthdata.org/covid/covid-19- vaccine-efficacy-summary Search Results: News, Blogs, & Social Media News CBC Experts encourage Sask. Residents to take AstraZeneca vaccine, affirm it’s safe. April 14, 2021. https://www.cbc.ca/news/canada/saskatchewan/experts-astrazeneca-myths-misinformation- 1.5986246 Evidence Search Report: INF031801v2 ESR 3 Why the U.S. recommended suspending Johnson & Johnson’s vaccine, and what it means for Canada. April 13, 2021. https://www.cbc.ca/news/health/johnson-johnson-vaccine-1.5986097 3 vaccinated hospitalized COVID patients ‘a bit surprising,’ says epidemiologist. April 13, 2021. https://www.cbc.ca/news/canada/new-brunswick/covid-19-vaccine-hospital-new-brunswick- epidemiologist-1.5983764 U.S. recommends ‘pause’ for Johnson & Johnson vaccine over clot reports. April 13, 2021. https://www.cbc.ca/news/world/johnson-and-johnson-vaccine-pause-1.5985110 Australia abandons COVID-19 vaccination targets after new advice on AstraZeneca shots. April 12, 2021. https://www.cbc.ca/news/health/australia-astrazeneca-vaccine-1.5983756 Top official admits China’s COVID-19 vaccines have low efficacy. April 11, 2021. https://www.cbc.ca/news/health/china-vaccines-covid-19-low-efficacy-1.5983594 Canada is losing the race between vaccines and variants as the 3rd wave worsens. April 8, 2021. https://www.cbc.ca/news/health/coronavirus-variants-canada-covid-19-vaccine-third-wave- 1.5978394 Study suggests vaccines may improve symptoms for some COVID-19 long-haulers. April 7, 2021. https://www.cbc.ca/news/health/covid-longhaulers-vaccines-1.5976738 Pfizer study suggests COVID-19 vaccine is safe, protective in younger teens. March 31, 2021. https://www.cbc.ca/news/health/pfizer-study-suggests-covid-19-vaccine-is-safe-protective-in- younger-teens-1.5970857 AstraZeneca-Oxford’s COVID-19 vaccine safety questions answered. March 31, 2021. https://www.cbc.ca/news/health/astrazeneca-oxford-vaccine-concerns-1.5951672 B.C. to open AstraZeneca COVID-19 vaccines for ages 55 to 65 in Lower Mainland. March 31, 2021. https://www.cbc.ca/news/canada/british-columbia/astrazeneca-vaccine-covid-19-update- mar-30-1.5969949 Pfizer study suggests COVID-19 vaccine is safe, protective in younger teens. March 31,2021. https://www.cbc.ca/news/health/pfizer-study-suggests-covid-19-vaccine-is-safe-protective-in- younger-teens-1.5970857 Here’s what we know so far about B.C.’s response to AstraZeneca vaccine concerns. March 30, 2021. https://www.cbc.ca/news/canada/british-columbia/bc-astrazeneca-covid-19-clots- 1.5969202 Doctors agree with pause of AstraZeneca-Oxford COVID-19 vaccine doses, but Manitobans have questions. March 30, 2021. https://www.cbc.ca/news/canada/manitoba/manitoba-covid-19- astrazeneca-vaccine-pause-1.5969235 Saskatchewan pauses AstraZeneca vaccinations for people under 55. March 29, 2021. https://www.cbc.ca/news/canada/saskatoon/covid-19-saskatchewan-1.5968597 Manitoba pauses use of AstraZeneca COVID-19 vaccine on people under 55. March 29, 2021. https://www.cbc.ca/news/canada/manitoba/manitoba-vaccine-update-march29-2021- 1.5968335 Quebec suspends giving doses of AstraZeneca to those under 55, though no issues reported in Canada. March 29, 2021. https://www.cbc.ca/news/canada/montreal/astrazeneca-quebec- suspended-1.5968451 N.L. pausing use of AstraZeneca-Oxford vaccine on people under 55. March 29, 2021. https://www.cbc.ca/news/canada/newfoundland-labrador/nl-covid-march-29-2021-1.5963405 Ontario suspending use of AstraZeneca vaccine for people under 55 following NACI recommendations. March 29, 2021. https://www.cbc.ca/news/canada/toronto/covid-19- ontario-march-29-2021-vaccine-doses-1.5967888 Evidence Search Report: INF031801v2 ESR 4 Alberta temporarily pauses AstraZeneca vaccine for people under 55. March 29, 2021. https://www.cbc.ca/news/canada/edmonton/deena-hinshaw-alberta-covid-1.5968291
Load more

Recommended publications
  • Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP)
    Morbidity and Mortality Weekly Report Recommendations and Reports February 8, 2002 / Vol. 51 / No. RR-2 General Recommendations on Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) INSIDE: Continuing Education Examination Centers for Disease Control and Prevention SAFER • HEALTHIER • PEOPLETM MMWR CONTENTS The MMWR series of publications is published by the Introduction ......................................................................... 1 Epidemiology Program Office, Centers for Disease Timing and Spacing of Immunobiologics .............................. 2 General Principles for Vaccine Scheduling ......................... 2 Control and Prevention (CDC), U.S. Department of Spacing of Multiple Doses of the Same Antigen ................ 2 Health and Human Services, Atlanta, GA 30333. Simultaneous Administration ............................................ 4 Nonsimultaneous Administration ...................................... 5 Spacing of Antibody-Containing Products and Vaccines ..... 6 SUGGESTED CITATION Interchangeability of Vaccines from Different Manufacturers 8 Centers for Disease Control and Prevention. General Lapsed Vaccination Schedule ............................................ 8 recommendations on immunization: recom- Unknown or Uncertain Vaccination Status ......................... 8 mendations of the Advisory Committee on Contraindications and Precautions ....................................... 8 Immunization Practices and the
    [Show full text]
  • CIOMS Guide to Vaccine Safety Communication
    2018 CIOMS Guide to Vaccine Safety Communication Report by Topic Group 3 of the CIOMS Working Group on Vaccine Safety Council for International Organizations of CIOMS Guide to Vaccine Safety Communication CIOMS Guide to Vaccine Medical Sciences (CIOMS) Geneva, Switzerland 2018 CIOMS CIOMS Guide to Vaccine Safety Communication Report by Topic Group 3 of the CIOMS Working Group on Vaccine Safety Council for International Organizations of Medical Sciences (CIOMS) Geneva,Geneva Switzerland 2014 2018 Copyright © 2018 by the Council for International Organizations of Medical Sciences (CIOMS) ISBN: 978-92-9036091-9 All rights reserved. CIOMS publications may be obtained directly from CIOMS using its website e-shop module at https://cioms.ch/shop/. Further information can be obtained from CIOMS P.O. Box 2100, CH-1211 Geneva 2, Switzerland, tel.: +41 22 791 6497, www.cioms.ch, e-mail: [email protected]. CIOMS publications are also available through the World Health Organization, WHO Press, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland. Citations: CIOMS Guide to vaccine safety communication. Report by topic group 3 of the CIOMS Working Group on Vaccine Safety. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS), 2018. Note on style: This publication uses the World Health Organization’s WHO style guide, 2nd Edition, 2013 (WHO/ KMS/WHP/13.1) wherever possible for spelling, punctuation, terminology and formatting which combines British and American English conventions. Disclaimer: The authors alone are responsible for the views expressed in this publication and those views do not necessarily represent the decisions, policies or views of their respective institutions or companies.
    [Show full text]
  • Top 10 Stories from the June 2021 AMA Special Meeting
    Top 10 stories from the June 2021 AMA Special Meeting JUN 17, 2021 Kevin B. O'Reilly News Editor Nearly 700 physicians, residents and medical students gathered for the June 2021 AMA Special Meeting of the AMA House of Delegates (HOD) to consider a wide array of proposals to help fulfill the AMA's core mission of promoting medicine and improving public health. As they have done since the global pandemic was declared last year, the delegates met virtually. Pandemic heroism sets path for work ahead “This is a consequential time in American history, and in the history of medicine,” new AMA President Gerald E. Harmon, MD, said in his inaugural address. The nation is “at war against seemingly formidable adversaries: the COVID-19 pandemic, which has led to the deaths of millions worldwide, and hundreds of thousands here at home, prolonged isolation and its effects on emotional and behavioral health, political and racial tension, and the immense battle to rid our health system—and society—of health disparities and racism.” Watch or read Dr. Harmon’s speech. Susan R. Bailey, MD, now the AMA’s immediate past president, told delegates that “no one has shouldered more in this pandemic than our courageous colleagues on the front lines—brave men and women from every state who have gone above and beyond in service to their patients and communities. You will remain in our hearts and in our thoughts long after this pandemic is over.” Watch or read Dr. Bailey’s speech. Executive Vice President and CEO James L. Madara, MD, detailed the role “a more nimble, focused” AMA played in supporting physicians during a once-in-a-generation public health crisis and how that response can be channeled to advance health equity.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Storage Best Practices for Frozen Vaccines-Fahrenheit
    Storage Best Practices for Frozen Vaccines–Fahrenheit (F) 1 Unpack vaccines immediately 1. Place the vaccines in trays or containers for proper air flow. 2. Put vaccines that are first to expire in front. HEP A - VFC 3. Keep vaccines in original boxes with lids closed to prevent exposure to light. 4. Separate and label vaccines by type and public (VFC) or private. 2 Thermostat should be at the factory-set or midpoint temperature setting Frozen Vaccines Too Cold! Within Range Too Warm! Take Action! Take Action! Report out-of-range temperatures immediately! -70° F -65° F -60° F -50° F -45° F -40° F -35° F 10° F 15° F -58° F 5° F 3 Use vaccine storage best practices Freezer Only DO temp range ✓ Do make sure the freezer door is closed! -58° F to 5° F ✓ Do use water bottles to help maintain consistent temperature. ✓ Do leave 2 to 3 inches between vaccine containers and freezer walls. don’t block vents ✓ Do post “Do Not Unplug” signs on freezer and by electrical outlet. do not unplug DON’T Don’t use dormitory-style refrigerator/freezer. Don’t use combo refrigerator/freezer unit. Don’t put food in freezer. Don’t store vaccines on shelves in freezer door. CS243541-D Revision December 2020 Distributed by Visit www.cdc.gov/vaccines/SandH or contact your state health department for more information. Test Your Knowledge 1 Which of the following units is the best for storing frozen vaccines? Freezer Freezer Freezer Freezer A. Full-size B. Full-size C. Stand-alone D.
    [Show full text]
  • Frequently Asked Questions About COVID-19
    doh.sd.gov/covid/ Frequently Asked Questions About COVID-19 VACCINE SAFETY Why should I get vaccinated for COVID-19? COVID-19 can cause serious illness or even death. There’s no way to know how COVID-19 will affect you. And if you get sick, you could spread the disease to friends, family, and others around you, putting their lives at risk. Getting a COVID-19 vaccine greatly reduces the risk that you’ll develop COVID- 19. The vaccines prevent nearly 100% of hospitalizations and deaths due to COVID-19. Are the COVID-19 vaccines safe? Yes. The COVID-19 vaccines available in the United States meet the FDA’s rigorous standards for safety and effectiveness. Tens of millions of people in the United States have received COVID-19 vaccines, and all COVID vaccines will continue to be monitored for safety. Serious health effects from vaccines are very rare. It’s highly unlikely that COVID-19 vaccines will cause long-term health problems. Also, there is no evidence at all that they will cause infertility or cancer. Your risk for serious health problems is much lower from the vaccine than your risk if you’re unvaccinated and get COVID-19. COVID-19 can leave you with heart and lung damage and other conditions that require long-term treatment. Vaccines are much safer paths to immunity than the disease itself. How can COVID-19 vaccines be safe since they were developed so fast? Safe COVID-19 vaccines were developed quickly through the use of a century of vaccine experience; technology that was new to vaccines but had been studied for two decades; a coronavirus vaccine already in development at the National Institutes of Health; and tens of thousands of volunteers for clinical trials that enabled rapid accumulation of data on safety and effectiveness.
    [Show full text]
  • CDC Vaccine Storage and Handling Guide
    Table of Contents General Information Vaccine Storage and Handling Best Practices 5 Selected Biologicals Diphtheria Toxoid-, Tetanus Toxoid- and acellular Pertussis-Containing Vaccines DTaP: DAPTACEL, Infanrix, Tripedia 11 DTaP-IPV: KINRIX 11 DTaP-HepB-IPV: Pediarix 11 DTaP-IPV/Hib: Pentacel 11 Haemophilus influenzae type b-Containing Vaccines Hib: ActHIB, Hiberix, PedvaxHIB 15 Hib-HepB: Comvax 15 DTaP-IPV/Hib: Pentacel 11 Hepatitis-Containing Vaccines HepA: Havrix, VAQTA 19 HepB: Engerix-B, Recombivax HB 19 HepA-HepB: Twinrix 19 Vaccine Storage and Handling Guide and Storage Vaccine National Center for Immunization and Respiratory Disease DTaP-HepB-IPV: Pediarix 11 Hib-HepB: Comvax 15 Human Papillomavirus Vaccines HPV2: Cervarix 23 HPV4: Gardasil 23 Vaccine Storage and Handling Guide —————————————————————————————— Page 2 Table of Contents Influenza Vaccines LAIV: FluMist 27 TIV: Afluria, Fluarix, FluLaval, Fluvirin, Fluzone, Fluzone High-Dose, Fluzone Intradermal 29 Measles-, Mumps- and Rubella-Containing Vaccine MMR: M-M-RII 33 MMRV: ProQuad 69 Meningococcal Vaccines MCV4: Menactra, Menveo 37 MPSV4: Menomune 41 Pneumococcal Vaccines PCV13: Prevnar 13 45 PPSV23: Pneumovax 23 45 Poliovirus-Containing Vaccine IPV: IPOL 49 DTaP-HepB-IPV: Pediarix 11 DTaP-IPV: KINRIX 11 Vaccine Storage and Handling Guide and Storage Vaccine National Center for Immunization and Respiratory Disease DTaP-IPV/Hib: Pentacel 11 Rotavirus Vaccines RV1: ROTARIX 53 RV5: RotaTeq 53 Tetanus Toxoid Vaccine TT: Tetanus Toxoid 57 Vaccine Storage and Handling Guide ——————————————————————————————
    [Show full text]
  • Prospecting for an HIV Vaccine D
    Brett-Major et al. Tropical Diseases, Travel Medicine and Vaccines (2017) 3:6 DOI 10.1186/s40794-017-0050-4 REVIEW Open Access Prospecting for an HIV vaccine D. M. Brett-Major1,2*, T. A. Crowell1,2 and N. L. Michael1 Abstract Human immunodeficiency virus (HIV) sets several challenges for the development of a preventative HIV vaccine. Predictable, protective natural immunity against HIV does not occur and so unlike most other diseases for which vaccines exist, there are few guideposts from natural infection. Nonetheless, six vaccine efficacy trials have occurred. One in particular, the Thai trial called RV144, showed partial protective efficacy and potential ways ahead to a better vaccine approach. This coupled with other lessons from studies of acute infections as well as an increasingly complex knowledge of HIV-related vaccine immunology bring hope that a vaccine solution might be reached for this pervasive and deadly pandemic. Keywords: Human immunodeficiency virus vaccine protective efficacy immunology review Background Why not already Human immunodeficiency virus (HIV) disease remains A reasonable person new to the global conversation one of the greatest threats to global public health. about HIV might ask, if an HIV vaccine is so critical and According to the World Health Organization (WHO), in the pandemic known for three decades, why do we not 2014 over one million people died from HIV, nearly already have an HIV vaccine? There is no simple answer thirty-seven million people had chronic infection and to this question, though an easy one is that people do two million people newly acquired infections [1]. Of not develop natural, protective immunity to HIV infec- those persons known to be HIV infected, only 35% tion and disease.
    [Show full text]
  • The Model of “Informed Refusal” for Vaccination: How to Fight Against Anti-Vaccinationist Misinformation Without Disregarding the Principle of Self-Determination
    Communication The Model of “Informed Refusal” for Vaccination: How to Fight against Anti-Vaccinationist Misinformation without Disregarding the Principle of Self-Determination Stefano D’Errico 1, Emanuela Turillazzi 2, Martina Zanon 1, Rocco Valerio Viola 3, Paola Frati 3,4 and Vittorio Fineschi 3,4,* 1 Department of Surgery, Medicine and Health, University of Trieste, 34149 Trieste, Italy; [email protected] (S.D.); [email protected] (M.Z.) 2 Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] 3 Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy; [email protected] (R.V.V.); [email protected] (P.F.) 4 IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Neuromed Mediterranean Neurological Institute, Via Atinense 18, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39 06 49912722 Abstract: Vaccines are arguably a public health success story as well as an incredibly cost-effective medical resource. Despite this, worldwide concerns about their safety are growing, with the risk of Citation: D’Errico, S.; Turillazzi, E.; increased morbidity and mortality in vaccine-preventable diseases because of vaccine refusal. The Zanon, M.; Viola, R.V.; Frati, P.; global political trend in developed countries is to increasingly reduce mandates and the compulsory Fineschi, V. The Model of “Informed nature of vaccination programs. This is due to strong opposition from anti-vaccination movements Refusal” For Vaccination: How to and groups. While these have existed since the beginnings of vaccinology, they have recently gained Fight Against Anti-Vaccinationist a strong foothold through massive exploitation of the media and especially the internet.
    [Show full text]
  • An Overview of COVID Vaccine Clinical Trial Results & Some Challenges
    An overview of COVID vaccine clinical trial results & some challenges DCVMN Webinar December 8th, 2020 Access to COVID-19 tools ACCESSACCESS TO TOCOVID-19 COVID-19 TOOLS TOOLS (ACT) (ACT) ACCELERATOR ACCELERATOR (ACT) accelerator A GlobalA GlobalCollaboration Collaboration to Accelerate tothe AccelerateDevelopment, the Production Development, and Equitable Production Access to New and Equitable AccessCOVID-19 to New diagnostics, COVID-19 therapeutics diagnostics, and vaccines therapeutics and vaccines VACCINES DIAGNOSTICS THERAPEUTICS (COVAX) Development & Manufacturing Led by CEPI, with industry Procurement and delivery at scale Led by Gavi Policy and allocation Led by WHO Key players SOURCE: (ACT) ACCELERATOR Commitment and Call to Action 24th April 2020 ACT-A / COVAX governance COVAX COORDINATION MEETING CEPI Board Co-Chair: Jane Halton Co-Chair: Dr. Ngozi Gavi Board Workstream leads + DCVMN and IFPMA-selected Reps As needed – R&D&M Chair; COVAX IPG Chair Development & Manufacturing Procurement and delivery Policy and allocation (COVAX) at scale Led by (with industry) Led by Led by R&D&M Investment Committee COVAX Independent Product Group Technical Review Group Portfolio Group Vaccine Teams SWAT teams RAG 3 COVAX SWAT teams are being set up as a joint platform to accelerate COVID- 19 Vaccine development and manufacturing by addressing common challenges together Timely and targeted Multilateral Knowledge-based Resource-efficient Addresses specific cross- Establishes a dialogue Identifies and collates Coordinates between developer technical and global joint effort most relevant materials different organizations/ challenges as they are across different COVID-19 and insights across the initiatives to limit raised and/or identified vaccines organizations broader COVID-19 duplications and ensure on an ongoing basis (incl.
    [Show full text]
  • Road to Recovery: Recovering from Post-Acute COVID-19 (Long COVID)
    Road to Recovery: Recovering from post-acute COVID-19 (long COVID) Information and Advice Name: _____________________________ Symptoms reported by patients with post-acute (long) COVID-19 2 Recovery from post-acute COVID-19 (long COVID), October 2020 What is COVID-19? Covid-19 is an infectious virus that mainly affects the lungs. It is transmitted through droplets created from sneezing and coughing. The virus enters the body via the nose, mouth and eyes. What is post-acute COVID-19 (long COVID)? It is the term for someone who has not recovered for several weeks or months following the start of symptoms that were suggestive of COVID, whether they were tested for COVID-19 or not. We do not yet know why some people’s recovery takes much longer than others. What are the symptoms of post-acute COVID-19 (long COVID)? The most commonly reported symptoms are: • Fatigue • Muscle, body aches • Difficulty breathing • As well as the physical symptoms listed, it is very common to experience feelings of anxiety and low mood. Controlling shortness of breath Relieving shortness of breath People who have had a respiratory illness can often feel short of breath (SOB) afterwards. Often daily tasks such as walking, getting dressed or doing chores around the house can cause this breathlessness. Feeling like you can’t catch your breath can make you panic or feel frightened. Learning to control these feelings of breathlessness is a skill that will help you to be less troubled by this and enable you to do more. When you are feeling breathless, do not panic.
    [Show full text]
  • Effectiveness of Pfizer-Biontech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    Morbidity and Mortality Weekly Report Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 Mark W. Tenforde, MD, PhD1; Samantha M. Olson, MPH1; Wesley H. Self, MD2; H. Keipp Talbot, MD2; Christopher J. Lindsell, PhD2; Jay S. Steingrub, MD3; Nathan I. Shapiro, MD4; Adit A. Ginde, MD5; David J. Douin, MD5; Matthew E. Prekker, MD6; Samuel M. Brown, MD7; Ithan D. Peltan, MD7; Michelle N. Gong, MD8; Amira Mohamed, MD8; Akram Khan, MD9; Matthew C. Exline, MD10; D. Clark Files, MD11; Kevin W. Gibbs, MD11; William B. Stubblefield, MD2; Jonathan D. Casey, MD2; Todd W. Rice, MD2; Carlos G. Grijalva, MD2; David N. Hager, MD, PhD12; Arber Shehu, MD12; Nida Qadir, MD13; Steven Y. Chang, MD, PhD13; Jennifer G. Wilson, MD14; Manjusha Gaglani, MBBS15,16; Kempapura Murthy, MPH15; Nicole Calhoun, LMSW, MPA15; Arnold S. Monto, MD17; Emily T. Martin, PhD17; Anurag Malani, MD18; Richard K. Zimmerman, MD19; Fernanda P. Silveira, MD19; Donald B. Middleton, MD19; Yuwei Zhu, MD2; Dayna Wyatt2; Meagan Stephenson, MPH1; Adrienne Baughman2; Kelsey N. Womack, PhD2; Kimberly W. Hart2; Miwako Kobayashi, MD1; Jennifer R. Verani, MD1; Manish M. Patel, MD1; IVY Network; HAIVEN Investigators On April 28, 2021, this report was posted as an MMWR Early ≥65 years. Vaccination is a critical tool for reducing severe Release on the MMWR website (https://www.cdc.gov/mmwr). COVID-19 in groups at high risk. Adults aged ≥65 years are at increased risk for severe outcomes Randomized clinical trials of vaccines that have received an from COVID-19 and were identified as a priority group to EUA in the United States showed efficacy of 94%–95% in receive the first COVID-19 vaccines approved for use under preventing COVID-19–associated illness (4,5).§ However, an Emergency Use Authorization (EUA) in the United States hospitalization is a rare outcome among patients with (1–3).
    [Show full text]